User:Ely.yatun/Erdafitinib

Pharmacogenomics
For Erdafitinib to be effective it is essential that the growth has susceptible FGFR3 or FGFR2 genetic alterations, because of that a genetic test is required to be done to verify that the medication will have good efficacy. Based on FDA statements the medication can only be approved after an isolated tumor specimen was tested for the presence of the previously mentioned FGFR genes.

Another gene that can help determine if this medication is appropriate for the patient is CYP2C9, more specifically CYP2C9 *3/*3. The both forms of the alleles that are present are *3 it is likely that patients will experience a 50% increase of drug concentration in blood, this can cause increased side effects and should be avoided if possible. Single *3 alleles presence is considered to be not impactful enough to cause the same increase in concertation of drug so it is safe to use in that case.